SCHEMBL2214911

SCHEMBL2214911

CCCc1nc(C(=O)O)cc2c3ccccc3n(CC)c12

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
HPGD P15428 3/20 0.44
MAPT P10636 4/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HTT P42858 2/20 0.44
GAA P10253 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
KDM4E B2RXH2 6/20 0.43
POLB P06746 2/20 0.43
PTGER4 P35408 4/20 0.43
LMNA P02545 3/20 0.42
PKM P14618 1/20 0.42
MAPK1 P28482 2/20 0.41
NPY5R Q15761 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PTGES O14684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2215730 0.93 ALDH1A1 (0.43) ALDH1A1HPGDMAPTKMT2AMEN1
SCHEMBL2214060 0.90 ALDH1A1 (0.48) ALDH1A1HPGDMAPTKMT2AMEN1
SCHEMBL2212262 0.90 PDE4A (0.48) ALDH1A1HPGDMAPTKMT2AMEN1
SCHEMBL2214686 0.88 KDM4E (0.45) ALDH1A1HPGDMAPTGAAKDM4E
SCHEMBL2214021 0.87 PLA2G2A (0.43) ALDH1A1HPGDKMT2AMEN1
SCHEMBL2215074 0.86 CNR2 (0.53) ALDH1A1HPGDMAPTGAAKDM4E
SCHEMBL2216828 0.85 PGR (0.46) ALDH1A1HPGDHTTKDM4ELMNA
SCHEMBL2216231 0.84 PTGER4 (0.54) ALDH1A1HPGDMAPTKMT2AMEN1
SCHEMBL2218201 0.83 AGTR1 (0.47) KDM4EL3MBTL1
SCHEMBL2216624 0.82 HSD17B10 (0.43) ALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1634881-B1 HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD (CN) 2011-07-27 EP claimed
US-20090227619-A1 Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) 2009-09-10 US claimed
US-8772311-B2 Harmine derivatives, intermediates used in their preparations, preparation processes and use thereof XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) 2014-07-08 US disclosed
EP-1634881-B1 HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD (CN) 2011-07-27 EP disclosed
US-20090227619-A1 Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) 2009-09-10 US disclosed
EP-1634881-A1 HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF Xinjiang Huashidan Pharmaceutical Research Co., Ltd. (CN) 2006-03-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227619-A1 Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo TPH1, HTR1F, TPH2 ALDH1A1 324/4885HPGD 822/4885MAPT 1483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.